These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 9231037)

  • 41. The novel cardiotonic agent EMD 53 998 is a potent "calcium sensitizer".
    Beier N; Harting J; Jonas R; Klockow M; Lues I; Haeusler G
    J Cardiovasc Pharmacol; 1991 Jul; 18(1):17-27. PubMed ID: 1719287
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels.
    Kaheinen P; Pollesello P; Levijoki J; Haikala H
    J Cardiovasc Pharmacol; 2001 Apr; 37(4):367-74. PubMed ID: 11300649
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evoked changes in cardiovascular function in rats by infusion of levosimendan, OR-1896 [(R)-N-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)acetamide], OR-1855 [(R)-6-(4-aminophenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one], dobutamine, and milrinone: comparative effects on peripheral resistance, cardiac output, dP/dt, pulse rate, and blood pressure.
    Segreti JA; Marsh KC; Polakowski JS; Fryer RM
    J Pharmacol Exp Ther; 2008 Apr; 325(1):331-40. PubMed ID: 18171907
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Selective inhibition of cAMP phosphodiesterase III activity by the cardiotonic agent saterinone in guinea pig myocardium.
    Brunkhorst D; von der Leyen H; Meyer W; Schmidt-Schumacher C; Scholz H
    Arzneimittelforschung; 1988 Sep; 38(9):1293-8. PubMed ID: 2852013
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dual regulation of myofilament Ca2+ sensitivity by levosimendan in normal and acidotic conditions in aequorin-loaded canine ventricular myocardium.
    Takahashi R; Endoh M
    Br J Pharmacol; 2005 Aug; 145(8):1143-52. PubMed ID: 15951828
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Levosimendan prevents doxorubicin-induced cardiotoxicity in time- and dose-dependent manner: implications for inotropy.
    Efentakis P; Varela A; Chavdoula E; Sigala F; Sanoudou D; Tenta R; Gioti K; Kostomitsopoulos N; Papapetropoulos A; Tasouli A; Farmakis D; Davos CH; Klinakis A; Suter T; Cokkinos DV; Iliodromitis EK; Wenzel P; Andreadou I
    Cardiovasc Res; 2020 Mar; 116(3):576-591. PubMed ID: 31228183
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The effects of milrinone and piroximone on intracellular calcium handling in working myocardium from the ferret.
    Gwathmey JK; Morgan JP
    Br J Pharmacol; 1985 May; 85(1):97-108. PubMed ID: 2992656
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Milrinone and levosimendan during porcine myocardial ischemia -- no effects on calcium overload and metabolism.
    Axelsson B; Johansson G; Abrahamsson P; Gupta A; Tydén H; Wouters P; Haney M
    Acta Anaesthesiol Scand; 2013 Jul; 57(6):719-28. PubMed ID: 23517167
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mechanism underlying the reduced positive inotropic effects of the phosphodiesterase III inhibitors pimobendan, adibendan and saterinone in failing as compared to nonfailing human cardiac muscle preparations.
    von der Leyen H; Mende U; Meyer W; Neumann J; Nose M; Schmitz W; Scholz H; Starbatty J; Stein B; Wenzlaff H
    Naunyn Schmiedebergs Arch Pharmacol; 1991 Jul; 344(1):90-100. PubMed ID: 1723153
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effect of positive inotropes on the failing human myocardium.
    Erdmann E
    Cardiology; 1997; 88 Suppl 2():7-11. PubMed ID: 9142430
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of the benzimidazole derivatives pimobendan and 2-(4-hydroxy-phenyl)-5-(5-methyl-3-oxo-4,5-dihydro-2H-6- pyridazinyl) benzimidazole . HCl on phosphodiesterase activity and force of contraction in guinea-pig hearts.
    Berger C; Meyer W; Scholz H; Starbatty J
    Arzneimittelforschung; 1985; 35(11):1668-73. PubMed ID: 2418846
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effects of levosimendan on [Ca2+]i in guinea-pig isolated ventricular myocytes.
    Lancaster MK; Cook SJ
    Eur J Pharmacol; 1997 Nov; 339(1):97-100. PubMed ID: 9450621
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of a calcium-sensitizing agent, levosimendan, on the postcardioplegic inotropic response of the myocardium.
    Lochner A; Colesky F; Genade S
    Cardiovasc Drugs Ther; 2000 Jun; 14(3):271-81. PubMed ID: 10935149
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Beneficial effects of the Ca(2+) sensitizer levosimendan in human myocardium.
    Brixius K; Reicke S; Schwinger RH
    Am J Physiol Heart Circ Physiol; 2002 Jan; 282(1):H131-7. PubMed ID: 11748056
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of Combined Milrinone and Levosimendan Treatment on Systolic and Diastolic Function During Postischemic Myocardial Dysfunction in a Porcine Model.
    Axelsson B; Häggmark S; Svenmarker S; Johansson G; Gupta A; Tydén H; Wouters P; Haney M
    J Cardiovasc Pharmacol Ther; 2016 Sep; 21(5):495-503. PubMed ID: 26837238
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Levosimendan, a new calcium-sensitizing inotrope for heart failure.
    Ng TM
    Pharmacotherapy; 2004 Oct; 24(10):1366-84. PubMed ID: 15628834
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan.
    Haikala H; Kaivola J; Nissinen E; Wall P; Levijoki J; Lindén IB
    J Mol Cell Cardiol; 1995 Sep; 27(9):1859-66. PubMed ID: 8523447
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of levosimendan on myocardial contractility and oxygen consumption.
    Todaka K; Wang J; Yi GH; Stennett R; Knecht M; Packer M; Burkhoff D
    J Pharmacol Exp Ther; 1996 Oct; 279(1):120-7. PubMed ID: 8858984
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Stereoselective binding of levosimendan to cardiac troponin C causes Ca2+-sensitization.
    Sorsa T; Pollesello P; Rosevear PR; Drakenberg T; Kilpeläinen I
    Eur J Pharmacol; 2004 Feb; 486(1):1-8. PubMed ID: 14751401
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Positive inotropic activity of 5-amino-6-cyano-1,3-dimethyl-1,2,3,4-tetrahydropyrido[2,3-d]pyrim idine-2,4-dione in cardiac muscle from guinea-pig and man. Part 6: Compounds with positive inotropic activity.
    Heber D; Heers C; Ravens U
    Pharmazie; 1993 Jul; 48(7):537-41. PubMed ID: 7692456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.